• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

EverlyWell Partners with Helix to Launch New Suite of DNA Tests

by Fred Pennic 07/25/2017 Leave a Comment

EverlyWell Convenient At-Home Health Testing

EverlyWell, a next-generation health testing platform has launched three new biomarker and genomics products that will expand its established suite of at-home lab testing kits that provide insights about health and wellness. The new tests, which harness DNA to yield personalized information about food sensitivity, metabolism, and breast milk DHA, were developed in collaboration with Helix, a personal genomics company that today launched the first online marketplace for DNA-based products. EverlyWell’s new products will be available on the Helix marketplace along with a diverse range of other DNA-based products focused on health, fitness, nutrition, family, ancestry and entertainment.

The first three products available in the Helix online marketplace include:

· Food Sensitivity+ ($249): Measure sensitivity to foods and the impact DNA may have on the ability to digest certain foods and nutrients.

· Metabolism+ ($149): Check current hormone levels and learn how DNA factors may affect weight through alterations in metabolism.

· Breast Milk DHA+ ($89): Learn how much omega-3 DHA is in a woman’s breast milk and if DNA may affect your levels of DHA.

With Helix, customers will only need to have their DNA sequenced once to utilize the new EverlyWell products. When a new Helix customer purchases an EverlyWell product via the Helix marketplace, they will receive two kits in the mail: one to collect a DNA sample and one to collect their biomarker sample. These kits will be returned in the postage-paid envelopes included with each kit. After returning the samples, biomarker results should be available within 5 days. For new Helix customers, the DNA-based results should be available within 6-8 weeks.

“We are proud to bring the latest in DNA sequencing technology to our customers through the Helix marketplace. Our selection as a Helix launch partner is further validation of EverlyWell’s platform and the exceptional consumer experience we’ve created,” says Julia Cheek, CEO and Founder, EverlyWell in a statement. “By sharing DNA information alongside key nutrition and metabolic biomarkers that we already offer, EverlyWell is now at the forefront of genomic and biomarker consumer testing.”

EverlyWell provides at-home lab testing kits with easy to understand results. They are the only company offering a suite of physician-reviewed lab tests that can be ordered and collected by consumers without leaving home. Test orders are reviewed and approved by independent board certified physicians. The EverlyWell platform currently offers 13 different at-home lab tests focused on sexual health, thyroid, metabolism, men’s health, and breast milk DHA testing, which the company is the exclusive provider of in the United States. 

 

Tagged With: DNA Testing, EverlyWell

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Most Popular

ViVE 2023 Executive Takeaways

VIVE 2023: 6 Digital Health Executives Share Their Key Takeaways

Survey: Clinician Burnout Is A Public Health Crisis Demanding Urgent Action

17 Execs Share How Health IT Can Address Clinician Burnout, Staffing, & Capacity

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Northwell Health Extends Contract with Allscripts Sunrise Platform Through 2027

Northwell to Deploy Epic Enterprise EHR Platform Across System

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Pfizer Acquires Seagen for $43B to Tackle Cancer

Pfizer Acquires Seagen for $43B to Tackle Cancer

5 Key Trends Driving Purchasing Decisions in Healthcare IT

5 Key Trends Driving Purchasing Decisions in Healthcare IT

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Dr. Arti Masturzo

Q/A: Dr. Masturzo Talks Addressing Food Insecurity with Patients

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |